Amendments to the Claims and Listing of the Claims:

Please cancel claims 2, 6 and 20-31, without prejudice, and amend claims 1, 3, 7-9, 16-19 and 32, without prejudice, as set forth in the following listing of the claims, which replaces all prior listings of the claims:

1. (Currently Amended) A composition for nasal delivery comprising zolpidem or a pharmaceutically acceptable salt thereof, wherein the composition is in the form of a solution and comprises 0.8 to 0.97 mg/ml of zolpidem (expressed as the free base).

2. (Canceled)

3. (Currently Amended) The composition according to claim[[2]] 1 in the form of an aqueous solution.

4. (Previously Presented) The composition according to claim 1, comprising a salt of zolpidem selected from the hydrochloride, mesilate, citrate, nitrate, lactate, maleate, tartrate, phosphate, succinate, fumarate and gluconate salts.

5. (Previously Presented) The composition according to claim 4, wherein the salt is the tartrate salt.

6. (Canceled)

7. (Currently Amended) The composition according to claim[[6]] 1, comprising from 24 to 80 mg/ml of zolpidem (expressed as the free base).

8. (Currently Amended) The composition according to claim[[6]] 1, comprising from 2.4 to 16 mg/ml of zolpidem (expressed as the free base).

9. (Currently Amended) The composition according to claim 1, ~~in the form of a solution and~~ further comprising a solubility enhancing agent.

10. (Previously Presented) The composition according to claim 9, wherein the solubility enhancing agent is a cyclodextrin.

11. (Previously Presented) The composition according to claim 10, wherein the cyclodextrin is sulfobutylether-β-cyclodextrin (SBE-CD).

12. (Previously Presented) The composition according to claim 11, comprising 50 to 700 mg/ml SBE-CD.

13. (Previously Presented) The composition according to claim 1, having a pH of from 3.0 to 8.0.

14. (Previously Presented) The composition according to claim 1, additionally comprising chitosan, a salt, a derivative thereof or a salt of a derivative thereof.

15. (Previously Presented) The composition according to claim 14, comprising from 0.5 to 50 mg/ml of chitosan, a salt, a derivative thereof or a salt of a derivative thereof.

16. (Currently Amended) The composition according to claim 1, ~~which~~ wherein the composition is an aqueous solution and comprises from 30 to 60 mg/ml of zolpidem tartrate, 100 to 300 mg/ml SBE-CD and 2 to 10 mg/ml of chitosan glutamate.

17. (Currently Amended) The composition according to claim 1, ~~which~~ wherein the composition is an aqueous solution and comprises from 3 to 20 mg/ml of zolpidem tartrate and 2 to 10 mg/ml of chitosan glutamate.

18. (Currently Amended) The composition according to claim 1, wherein the composition is in the form of a non-aqueous solution.

19. (Currently Amended) The composition according to claim 18, further comprising at least one of ethanol, propylene glycol, polyethylene glycol, glycofurol, benzyl benzoate and a polyoxyethylene castor oil derivative.

20. – 31. (Canceled)

32. (Currently Amended) A method of administering zolpidem or a pharmaceutically acceptable salt thereof to a patient in need thereof, which method ~~comprise~~ comprises the intranasal administration of a composition as defined in claim 1.

33. (Previously Presented) A method of treating or preventing insomnia, which method comprises the intranasal administration of a composition as defined in claim 1.

34. (Previously Presented) A method of treating a neurological disorder or Parkinson's disease, which method comprises the intranasal administration of a composition as defined in claim 1.

35. (Previously Presented) A method according to claim 34, wherein the neurological disorder is one arising from brain trauma, stroke or spinocerebellar ataxia.

36. (Previously Presented) A nasal drug delivery device or a dose cartridge for use in a nasal drug delivery device comprising a composition as defined in claim 1.